- Bruker Corp has reduced its full-year adjusted earnings per share (EPS) forecast.
- The new adjusted EPS forecast for 2025 ranges between $1.95 and $2.05.
- Previously, the company expected the EPS to be between $2.40 and $2.48, with the market estimate at $2.42.
- For the second quarter, Bruker’s revenue totaled $797.4 million, which was below the estimated $810.2 million.
- The adjusted EPS for the second quarter was 32 cents, falling short of the estimated 42 cents.
- Bruker’s expected adjusted EPS for FY 2025 is lower than its FY 2024 non-GAAP EPS of $2.41.
- The company’s stock maintains varied evaluations: 7 buy recommendations, 6 holds, and 1 sell.
A look at Bruker Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Bruker Corp has a moderate outlook for its value, with a score of 3. This indicates that the company is reasonably priced compared to its intrinsic value. However, in terms of dividend, growth, resilience, and momentum, Bruker Corp has scores of 2 or 3, reflecting a more neutral stance in these areas. The company designs, manufactures, and markets specialized life science systems and field analytical systems for substance detection. Additionally, Bruker develops research tools using X-ray technology, indicating a focus on innovation and advanced materials.
Looking ahead, Bruker Corp may benefit from its solid value rating and moderate momentum score, suggesting the potential for steady growth. Although its dividend, growth, and resilience scores are not as high, the company’s innovative approach in life science systems and X-ray technology could drive future advancements and market opportunities. Investors may find Bruker Corp to be a promising option for long-term investment, with room for expansion and development in its niche markets.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
